Data availability
Not applicable.
References
FDA Briefing document joint meeting of the nonprescription drugs advisory committee and the obstetrics, reproductive, and urologic drugs advisory committee May 9, 2023 – May 10, 2023 https://www.fda.gov/media/167892/download. Accessed 29 June 2023.
Catlin JR, Brass EP. The effectiveness of nonprescription drug labels in the United States: insights from recent research and opportunities for the future. Pharmacy (Basel). 2018;6:119.
FDA Guidance for industry self-selection studies for nonprescription drug products, https://www.fda.gov/files/drugs/published/Self-Selection-Studies-for-Nonprescription-Drug-Products.pdf. Accessed 29 June 2023.
Merriam-Webster Dictionary. “De-“. https://www.merriam-webster.com/dictionary/DE. Accessed 16 Aug 2023.
Merriam-Webster Dictionary. “Deselect”. https://www.merriam-webster.com/dictionary/deselect. Accessed 16 Aug 2023.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author is a consultant to companies involved with the development of nonprescription drugs.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Brass, E.P. The Term ‘Deselect’ is Ambiguous as Used in Research Studies to Support Prescription to Nonprescription Switches. Ther Innov Regul Sci 58, 16–17 (2024). https://doi.org/10.1007/s43441-023-00590-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43441-023-00590-6